KasivisvanathanVRannikkoASBorghiM, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378(19):1767-1777.
2.
ThompsonBTKamaliKAbdolellM, et al. The diagnostic yield of MRI–transrectal US fusion prostate biopsy in men with suspected prostate cancer. Can Assoc Radiol J. In press.
3.
OertherBNedelcuAEngelH, et al. Update on PI-RADS Version 2.1 diagnostic performance benchmarks for prostate MRI: systematic review and meta-analysis. Radiology. 2024;312(2):e233337.
4.
TurkbeyBRosenkrantzABHaiderMA, et al. PI-RADS v2.1: 2019 update of the Prostate Imaging Reporting and Data System. Eur Urol. 2019;76(3):340-351.
5.
ChangSDReinholdCKirkpatrickIDC, et al. Canadian Association of Radiologists Prostate MRI white paper. Can Assoc Radiol J. 2022;73(4):626-638.
6.
KinnairdALugerFCashH, et al. Microultrasonography-guided vs MRI-guided biopsy for prostate cancer diagnosis: the OPTIMUM randomized clinical trial. JAMA. 2025;333(19):1679-1687.
7.
WagnerMSamjiK. Limited utility of dynamic contrast enhancement imaging sequences within the PI-RADS v2.1 classification scheme: a retrospective cross-sectional study of MRI reports. Can Assoc Radiol J. 2025;76(1):87-93.
8.
SchiedaNNishaYHadziomerovicAR, et al. Comparison of positive predictive values of biparametric and multiparametric MRI-directed transrectal US-guided targeted prostate biopsy. Radiology. 2024;311(3):e231383.
9.
WestphalenACMcCullochCEAnaokarJM, et al. Variability of the positive predictive value of PI-RADS for prostate MRI across 26 centers. Radiology. 2020;296(1):76-84.
